This source explores DT-109, an experimental tripeptide that represents a novel approach to treating metabolic and cardiovascular diseases. By analyzing its structure and mechanism, the text highlights how this small molecule distinguishes itself from popular weight-loss drugs by stimulating natural GLP-1 production and directly altering liver metabolism.